期刊文献+

乳腺导管内增生性病变及浸润性癌中雌激素受体亚型表达的比较性研究 被引量:2

Expression of estrogen receptors α and β in introductal proliferative lesions and invasive carcinoma of the breast: A comparative study
在线阅读 下载PDF
导出
摘要 目的探讨雌激素受体亚型(ERα和ERβ)在乳腺导管内增生性病变及浸润性乳腺癌中的表达及其相互关系。方法采用免疫组织化学法检测正常乳腺组织6例,乳腺导管普通型增生(UDH)11例,非典型性导管增生(ADH)7例,导管原位癌(DCIS)23例(其中Ⅰ级8例,Ⅱ级11例,Ⅲ级4例)及浸润性乳腺癌(IBC)11例中ERα和ERβ的表达。结果ERα的表达在UDH、ADH及Ⅰ级DCIS中呈逐渐增高趋势,而在Ⅲ级DCIS及IBC中的表达降低,ERα的表达在UDH与DCIS中差异具有统计学意义(P<0.05);从正常乳腺组织到UDH、ADH、DCIS至IBC的发展过程中ERβ的表达逐渐降低,ERβ的表达在正常乳腺组织与ADH、DCIS和IBC中以及UDH与DCIS和IBC中的差异具有统计学意义(P<0.05);ERα和ERβ之间表达没有相关性(P>0.05)。结论从乳腺良性增生性病变到浸润性癌的发展过程中ERα和ERβ的表达各不相同,两者可能通过不同的机制参与癌变过程。 Objective To explore the expressions of estrogen receptors a and β in introduetal proliferative lesions and invasive carcinoma of the breast. Methods Immtmohistochemistry was used to determine the expressions of ERa and β in 11 eases of usual ductal hyperplasia(UDH), 7 atypical ductal hyperplasia(ADH), 23 ductal carcinomas in situ(DICS) (8 DCIS Ⅰ , 11 DCIS Ⅱ ,4 DCIS Ⅲ ) and 11 invasive breast carcinomas(IBC). Results The expression level of ERa increased in UDH, ADH and low grade DCIS, while it decreased in high grade DCIS and IBC. The expression of ERα was higher in UDH than in DCIS( P 〈 0.05). The expression of EPβ decreased in the transformation from normal breast tissues to UDH, ADH, DCIS and IBC, and there were significant differences between normal breast tissues and ADH, DCIS, IBC, as well as among UDH and DCIS, IBC( P 〈 0.05). No correlation was found between the expressions of ERα and FRβ( P 〉 0. 05). Conclusions The expressions of ERα and 13 are different in the transformation from introduetal proliferative lesions to breast carcinoma, and they may act by different mechanisms in carcinogenesis.
出处 《山东大学学报(医学版)》 CAS 北大核心 2008年第1期72-75,F0003,共5页 Journal of Shandong University:Health Sciences
关键词 乳腺肿瘤 导管内增生性病变 受体 雌激素 Breast neoplasms Introduetal proliferative lesions Receptor, estrogen
  • 相关文献

参考文献14

  • 1Kuiper G G, Enmark E, Peho-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary [ J ]. Proc Natl Acad Sci USA, 1996, 93(1).
  • 2Fattaneh A, Peter D. WHO classification of tumours. Pathology & genetics, Tumours of the breast and female genital organs [ M]. IARC Press, Lyon, 2003 : 19.
  • 3Muramatsu M, Inoue S. Estrogen receptors: how do they control reproductive and nonreproductive functions [ J ]. Biochem Biophys Res Commun, 2000, 270( 1 ) : 1-10.
  • 4Ogawa S, Inoue S, Watanabe T, et al. The complete primary structure of human estrogen receptor beta (hER beta)and its her-erodimerization with ER alpha in vivo and in vitro [ J]. Biochem Biophys Res Commun, 1998, 243( 1 ):122-126.
  • 5Kuiper G G, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta[J]. Endocrinology, 1997, 138(3) :863-870.
  • 6Shaaban A M, O'Neill P A, Davies M P, et al. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia [ J ]. Am J Surg Pathol, 2003, 27: 1502-1512.
  • 7Shaaban A M, Jarvis C, Moore F, et al. Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome [ J]. Am J Sttrg Pathol, 2005, 29 (12) : 1593-1599.
  • 8Roger P, Sahla M E, Makela S, et al. Decreased expression of receptor beta protein in proliferative preinvasive mammary tumors[J]. Cancer Res, 2001, 61(6):2537-2541.
  • 9Couse J F, Korach K S. Estrogen receptor null mice: what have we learned and where will they lead us? [ J]. Endocr Rev, 1999, 20 (3):358-417.
  • 10Paruthiyil S, Parmar H, Kerekatte V, et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor. formation by causing a G2 cell cycle arrest[J]. Cancer Res, 2004, 64(1) :423-428.

同被引文献33

  • 1李美蓉,范松青,张利群,蒋谊.乳腺癌激素受体和癌基因的表达及临床意义[J].中国医师杂志,2006,8(1):34-37. 被引量:5
  • 2封敏,黄艳春,赵锋.乳腺癌组织中C-erbB-2基因蛋白的表达及其意义[J].新疆医科大学学报,2006,29(10):976-978. 被引量:2
  • 3Cherubini M, Baxa P, Guarino G. The oestrogen-progesterone receptor ratio: an indicator of breast cancer evolution[ J ]. Chir Ital, 2002, 54(4) : 423-428.
  • 4Riou G, Mathieu MC, Barrois M, et al. C-erbB-2(HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients [ J ]. Int J Cancer, 2001, 95(4) : 266-270.
  • 5Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendation for human epidermal growth factor 2 testing in breast cancer[J]. Arch Pathol Lab Med, 2007, 131 ( 1 ) : 18-43.
  • 6Mylonas I, Makovitzky J, Jeschke U, et al. Expression of HER2/neu, steroid receptors( ER and PR) , Ki67 and P53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone [J]. Anticancer Res, 2005, 25(3A) : 1719-1723.
  • 7Beenken SW, Grizzle WE, Crowe DR, et al. Molecular biomarkers for breast cancer prognosis : coexpression of C-erbB-2 and P53[J]. Ann Surg, 2001,233(5) : 630-638.
  • 8Perou CM, Sφrlie T, Eisen MB, et al. Molecular portraits of human breast tumors[J]. Nature, 2000, 406(6797) : 747-752.
  • 9Payton-Stewart F,Tilghman SL,Williams LG.Benzimidazoles diminish ERE transcriptional activity and cell growth in breast cancer cells[J].Biochem Biophys Res Commun,2014,450(4):1358-1362.
  • 10Locker GY.Hormonal therapy of breast cancer[J].Cancer Treat Rev,1998,24(3):221-240.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部